Cell therapy weekly: FDA to add 50 additional reviewers, expecting 200 INDs a year by 2020
This week: Hematopoietic stem cell transplantation more effective against MS than existing treatments and xeno-free method produces mesenchymal progenitor cells, moving one step closer to clinical-grade bone.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>